Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease

(1) Background: GP2017 is one of the biosimilar drugs of adalimumab, one of the anti-TNF agents used for inflammatory bowel disease (IBD). To date, there is little real-world data about the use of GP2017 in IBD patients. The aim of our study was to evaluate the effectiveness and safety of this biosi...

Full description

Bibliographic Details
Main Authors: Marta Vernero, Cristina Bezzio, Davide G. Ribaldone, Stefania Costa, Davide Scalvini, Elisa Tribocco, Gianpiero Manes, Simone Saibeni
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Journal of Clinical Medicine
Subjects:
adalimumab
biosimilar
GP2017
inflammatory bowel disease
ulcerative colitis
Crohn’s disease
Online Access:https://www.mdpi.com/2077-0383/12/21/6839

Internet

https://www.mdpi.com/2077-0383/12/21/6839

Similar Items